How Cancer Patients Perceive Clinical Trials (CTs) in the Era of CTs: Current Perception and Its Differences Between Common and Rare Cancers
- 104 Downloads
Perception has recently been highlighted as a critical determinant for participation in clinical trials (CTs) among cancer patients. We evaluated cancer patients’ current perceptions of CTs using the PARTAKE questionnaires, focusing on differences between patients with common and rare cancers. From November 2015 to May 2017, we prospectively surveyed patients who had received anti-cancer treatment at Asan Medical Center. Among 333 respondents, 70.9% had common and 29.1% had rare cancers. In the cohort, 87.7% of patients with common cancers and 75.3% of patients with rare cancers answered that they heard of and knew about CTs. However, willingness to participate in CTs was expressed only in approximately 56% of patients, although it was significantly associated with awareness and perception. Surprisingly, patients with rare cancers when compared with patients with common cancers showed significantly lower levels of awareness and perception (64.2% vs 79.9%, p = 0.003 and 77.3% vs 91.9%, p < 0.001), and consequently less willingness to participate in CTs (47.4% vs 58.9%, p = 0.06). In addition, cancer patients still harbored fear and concerns about safety and reward of CTs, and demonstrated substantial lack of knowledge about the voluntary nature of CTs, which was more obvious in patients with rare cancers. We identified relatively modest willingness of cancer patients to participate in CTs regardless of generally favorable perception. These findings are highlighted by the more negative perception of CTs among patients with rare cancers relative to those with common cancers. Further education and encouragement by research and public entities seem essential to improve motivation of CTs in cancer patients beyond good perception, especially for patients with rare cancers.
KeywordsClinical trial Current perception Rare cancer Common cancer Difference
The current research was supported by two grants from the Korea Health Technology R&D Project of the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI14C1061, HI18C2383).
JHP reviewed the literature, prepared and designed the analysis of data, and drafted and revised the manuscript. JSL, out statistician, made substantial contributions to the methodological process with the whole statistical analysis presented in the study. HYK made a core assistance in directing and proceeding PARTAKE survey and contributed to data management. All other listed co-authors contributed to enrollment of patients for they, as physician oncologist and co-investigators, primarily introduced the scope and aim of the current survey to their patients. TWK initially inspired the conception and design of the study and finally gave final approval of the version to be published. All authors read and approved the final manuscript.
Compliance with Ethical Standards
The study protocol was reviewed and approved by the Institutional Review Board (IRB approval number: 2014-1061) of Asan Medical Center and was conducted in full accordance with the guidelines for Good Clinical Practice and the Declaration of Helsinki.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.Lara PN Jr, Paterniti DA, Chiechi C, Turrell C, Morain C, Horan N, Montell L, Gonzalez J, Davis S, Umutyan A, Martel CL, Gandara DR, Wun T, Beckett LA, Chen MS Jr (2005) Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol 23(36):9282–9289CrossRefPubMedGoogle Scholar
- 3.Lim Y, Lim JM, Jeong WJ, Lee KH, Keam B, Kim TY, Kim TM, Han SW, Oh DY, Kim DW, Kim TY, Heo DS, Bang YJ, Im SA (2017) Korean cancer patients' awareness of clinical trials, perceptions on the benefit and willingness to participate. Cancer Res Treat 49(4):1033–1043CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Kim JW, Kim SJ, Chung YH, Kwon JH, Lee HJ, Chung YJ, Kim YJ, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ (2008) Cancer patients' awareness of clinical trials, perceptions on the benefit and willingness to participate: Korean perspectives. Br J Cancer 99(10):1593–1599CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher H, Earl H, Ray-Coquard I, Paul J, Blay JY, Whelan J, Panageas K, Wheatley K, Harrington K, Licitra L, Billingham L, Hensley M, McCabe M, Patel PM, Carvajal R, Wilson R, Glynne-Jones R, McWilliams R, Leyvraz S, Rao S, Nicholson S, Filiaci V, Negrouk A, Lacombe D, Dupont E, Pauporté I, Welch JJ, Law K, Trimble T, Seymour M (2015) Clinical trial designs for rare diseases: studies developed and discussed by the international rare cancers initiative. Eur J Cancer 51(3):271–281CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Shirazee N, Ives A, Collins J, Phillips M, Preen D (2016) Patterns in clinical trial enrollment and supportive care services provision among adolescents and young adults diagnosed with having cancer during the period 2000-2004 in Western Australia. J Adolesc Young Adult Oncol 5(3):254–260CrossRefPubMedGoogle Scholar
- 22.Group. RW. Cancer list. [cited 2018 Sep 30]. Available from http://www.rarecareeu/rarecarenet/indexphp/cancerlist
- 26.ClinicalTrials.gov. [Internet]. Bethesda MUSNIoHccM. [cited 2018 Sep 30]. Available from: https://clinicaltrialsgov/ct2
- 28.AACR Project GENIE: Powering precision medicine through an international consortium. Cancer Discov 2017;7(8):818–31Google Scholar
- 29.[Internet] S. [citied 2018 Sep 30]. Available from https://www.swog.org/clinical-trials/s1609